Yongjiang Li

Yongjiang Li

Auto-generated profile, based on publicly available information

Yongjiang Li

Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
ZHZhongshan He
Zhongshan He
WCWei Chen
Wei Chen
Kuan HuKuan Hu
Kuan Hu
YLYaoyao Luo
Yaoyao Luo
WZWanqin Zeng
Wanqin Zeng
WTWei Tao
Wei Tao

11 January 2021 in Drug Delivery
Verified
Journal Article
Open access
JWJun-Yong Wu
Jun-Yong Wu
YLYong-Jiang Li
Yong-Jiang Li
XHXiong-Bin Hu
Xiong-Bin Hu
SHSi Huang
Si Huang
DXDa-Xiong Xiang
Da-Xiong Xiang
Extracellular vesicles (EVs) are nanovesicles involved in multiple biological functions. Small EVs (sEVs) are emerging as therapeutics and drug delivery systems for their contents, natural carrier properties, and nanoscale size. Despite various clinical application potentials, little is known about the effects of storage conditions on sEVs for functional analysis and therapeutic use. In this study, we evaluated the stability of sEVs stored at 4 °C, −20 °C, and −80 °C up to 28 days and compared them to fresh sEVs. Also, the effect of freeze-thawing circles on the quantity of sEVs was assessed. We found that different storage temperatures, along with shelf life, impact the stability of sEVs when compared to freshly isolated sEVs. Storage changes the size distribution, decreases quantity and contents, and impacts cellular uptake and biodistribution of sEVs. For functional studies, isolated sEVs are suggested to be analyzed freshly or stored at 4 °C or −20 °C for short-term preservation depending on study design; but −80 °C condition would be more preferable for long-term preservation of sEVs for therapeutic application.

1 December 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
YLYong-Jiang Li
Yong-Jiang Li
JWJun-Yong Wu
Jun-Yong Wu
JWJie-Min Wang
Jie-Min Wang
XHXiong-Bin Hu
Xiong-Bin Hu
DXDa-Xiong Xiang
Da-Xiong Xiang

1 February 2022 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JCJia-Xin Cai
Jia-Xin Cai
JLJi-Hua Liu
Ji-Hua Liu
JWJun-Yong Wu
Jun-Yong Wu
YLYong-Jiang Li
Yong-Jiang Li
XQXiao-Han Qiu
Xiao-Han Qiu
DXDa-Xiong Xiang
Da-Xiong Xiang
Purpose: In order to prepare a biomimetic nano-carrier which has inflammatory chemotaxis, homologous targeting and reduce immune clearance, for targeted chemotherapy of osteosarcoma, we fabricated the paclitaxel-loaded poly(lactic-co-glycolic) acid (PLGA) nanoparticles coated with 143B-RAW hybrid membrane ([email protected][143B-RAW] NPs) and evaluate its anti-cancer efficacy in vitro and vivo. Methods: [email protected][143B-RAW] NPs were prepared by the ultrasonic method and were characterized by size, zeta potential, polymer dispersion index (PDI), Coomassie bright blue staining, transmission electron microscopy (TEM) and high performance liquid chromatography (HPLC). Cellular uptake, cell viability assay, flow cytometry and chemotactic effect of [email protected][143B-RAW] NPs were evaluated in vitro. Biodistribution, anti-cancer therapeutic efficacy and safety of [email protected][143B-RAW] NPs were evaluated in 143B osteosarcoma xenograft mice. Results: The hybrid membrane successfully coated onto the surface of PLGA nanoparticles. [email protected][143B-RAW] NPs had a drug loading capacity of 4.24 ± 0.02% and showed targeting ability to osteosarcoma. [email protected][143B-RAW] NPs showed high cellular uptake and improved anti-cancer efficacy against 143B cells. More importantly, [email protected][143B-RAW] NPs treatment suppressed tumor growth in tumor-bearing mice with minimal damage to normal tissues. Conclusion: [email protected][143B-RAW] NPs could be used for targeted drug delivery and osteosarcoma therapy.

1 January 2018 in Drug Delivery
Verified
Journal Article
Open access
JWJun-Yong Wu
Jun-Yong Wu
YLYong-Jiang Li
Yong-Jiang Li
LYLe Yang
Le Yang
YHYi-Yun Hu
Yi-Yun Hu
XHXiong-Bin Hu
Xiong-Bin Hu
DXDa-Xiong Xiang
Da-Xiong Xiang
Puerarin (PUE) and tetramethylpyrazine (TMP) are central nervous system (CNS) drugs used in cerebrovascular diseases. Poor brain–blood barrier (BBB) permeability limited their clinical application. Borneol and α-asarone have been proposed as an oral brain-targeting enhancer. In this study, we aimed to first evaluate the ‘orifice-opening’ effect of borneol and α-asarone, both aromatic resuscitation drugs, on improvement of brain delivery of PUE and TMP and second to investigate whether the enhancing effects were associated with adenosine receptors (ARs)-mediated trans-BBB pathway. In vitro BBB model was established and borneol and α-asarone significantly increased the cumulative amount of permeated PUE and TMP and the enhancing effects could be counteracted by AR inhibitors. Borneol and α-asarone could decrease expression of ZO-1, an important BBB junction protein, but inversely increase the expression of A1AR and A2AAR. In vivo pharmacokinetic study also confirmed that oral co-administration of borneol or α-asarone significantly increased AUCbrain for PUE and TMP. These results suggested that borneol and α-asarone are both effective adjuvant agents for delivery of PUE and TMP to the brain.

1 January 2021 in Drug Delivery
Verified
Journal Article
Open access
YLYong-Jiang Li
Yong-Jiang Li
JWJun-Yong Wu
Jun-Yong Wu
JLJihua Liu
Jihua Liu
XQXiaohan Qiu
Xiaohan Qiu
WXWenjie Xu
Wenjie Xu
DXDa-Xiong Xiang
Da-Xiong Xiang
Brain drug delivery remains a major difficulty for several challenges including the blood–brain barrier, lesion spot targeting, and stability during circulation. Blood cells including erythrocytes, platelets, and various subpopulations of leukocytes have distinct features such as long-circulation, natural targeting, and chemotaxis. The development of biomimetic drug delivery systems based on blood cells for brain drug delivery is growing fast by using living cells, membrane coating nanotechnology, or cell membrane-derived nanovesicles. Blood cell-based vehicles are superior delivery systems for their engineering feasibility and versatile delivery ability of chemicals, proteins, and all kinds of nanoparticles. Here, we focus on advances of blood cell-based biomimetic carriers for from blood to brain drug delivery and discuss their translational challenges in the future.